Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 29;22(9):1233-1234.
doi: 10.1093/neuonc/noaa170.

Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma

Karolina Woroniecka  1 , Peter E Fecci  1   2
Affiliations

Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma

Karolina Woroniecka et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

References

    1. Woroniecka K, Chongsathidkiet P, Rhodin K, et al. . T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175–4186. - PMC - PubMed
    1. Chongsathidkiet P, Jackson C, Koyama S, et al. . Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–1468. - PMC - PubMed
    1. Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T cell dysfunction in glioblastoma: applying a new framework. Clin. Cancer Res. 2018;24(16):3792–3802. - PMC - PubMed
    1. Sampson JH, Heimberger AB, Archer GE, et al. . Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–4729. - PMC - PubMed
    1. Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779–91794. - PMC - PubMed

Substances

Associated data